)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Dianthus Therapeutics
Dianthus Therapeutics (DNTH) investor relations material
Dianthus Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Key developments and pipeline updates
2025 marked a transformational year with positive phase 2 data in myasthenia gravis and the in-licensing of DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL.
Two clinical-stage products are advancing: clasiprubart (lead program) and DNTH212, with major catalysts expected in 2026 for CIDP and MMN indications.
DNTH212's next steps include announcing three target indications in the first half of 2026 and reporting top-line results from a healthy volunteer study in the second half of 2026.
CIDP program and clinical trial strategy
The phase 3 Captivate study in CIDP is progressing ahead of schedule, with interim responder analysis for the first 40 patients expected in Q2 2026.
Efficacy benchmarks are set to match or exceed riliprubart, aiming for a 40%-50% responder rate and potentially reducing the trial's higher dose arm for efficiency.
The trial design allows refractory patients and uses a rapid switch from IVIG, differentiating it from previous studies and aiming for broader applicability.
If efficacy is confirmed, the program could neutralize competitors' time-to-market advantage and support strong market positioning.
MMN and MG program differentiation
MMN program aims for similar or superior efficacy to empasiprubart, with advantages in dosing (subcutaneous auto-injector) and safety (no box warning expected).
Potency data suggest the product is significantly more potent than empasiprubart, with ongoing studies to confirm if this translates to higher efficacy.
MG program phase 2 data showed robust efficacy, especially in more severe patients, and phase 3 will implement stricter screening to control placebo response.
Once-a-month dosing is being tested, leveraging long half-life and strong efficacy at lower inhibition levels.
Impact of dropping 600mg arm on CIDP trial timeline
Clasiprubart's safety advantage vs empaciperbart MMN
How to achieve $5B+ peak sales for clasiprubart
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dianthus Therapeutics earnings date
Q4 202511 Mar, 2026
Dianthus Therapeutics
Next Dianthus Therapeutics earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage